Thereby, the data raise the possibility that topoisomerase inhibitors (topotecan or irinotecan) might be clinically useful in neuroblastoma MYCN amplified or MYCN non-amplified patients with ATRX loss-of-function, as was observed in patient NB1. This evidence concerns the gene ATRX and neuroblastoma.